0
Novo Nordisk Inc. has announced the FDA’s approval of insulin detemir injection of rDNA origin (Levemir®) for use in children. This basal (long-acting) form of insulin lasts for up to 24 hours and causes little weight change in adults.
It is indicated for once-daily or twice-daily subcutaneous administration for adults and children with type-1 diabetes mellitus or adults with type-2 diabetes mellitus who require long-acting insulin to control hyperglycemia.
This product was approved for use in adults in June 2005.
